S. Wyrick

发表

Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods.

D. E. Nichols, R. Mailman, A. Tropsha, 1999, Journal of medicinal chemistry.

Effects of [(N-alkyl-1,3-dihydro-1-oxoisoindolin-5-yl)oxy]alkanoic acids on chloride transport in primary astroglial cultures.

S. Wyrick, C. Waller, H. M. Park, 1994, Journal of pharmaceutical sciences.

High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.

S. Wyrick, S. Chaney, F. Luo, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.

S. Wyrick, S. Chaney, F. Luo, 1998, Oncology research.

Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.

S. Wyrick, S. Chaney, G. Gibbons, 1988, Cancer research.

An Unexpected Biotransformation Pathway for Tetrachloro-( < / , /-fra / is )-l , 2-diaminocyclohexaneplatinum ( IV ) ( Tetraplatin ) in the LI 210 Cell Line 1

S. Wyrick, P. Podhasky, G. Gibbons, 2006 .

Putative σ3 sites in mammalian brain have histamine H1 receptor properties: evidence from ligand binding and distribution studies with the novel H1 radioligand [ 3 H ]-(−)-trans-1-phenyl-3-aminotetralin

S. Wyrick, R. Booth, C. Owens, 1999, Brain Research.

The Effects of Phthalimide and Saccharin Derivatives on Low-Density Lipoprotein (LDL) and High-Density Lipoprotein (HDL) Receptor Activity and Related Enzyme Activities

S. Wyrick, I. Hall, O. T. Wong, 1988, Pharmaceutical Research.

In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.

S. Wyrick, S. Chaney, G. K. Till, 1990, Cancer research.

Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.

S. Wyrick, S. Chaney, G. Gibbons, 1989, Cancer research.

Tritium labelled 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ALP) and 1-S-hexadecyl-2-O-ethyl-rac-thioglycero-3-phosphocholine (Thio-ALP)

C. Piantadosi, E. Modest, S. Wyrick, 1989 .

Tritiated hexadecyl platelet activating factor (PAF)

S. Wyrick, J. O'flaherty, R. Wykle, 1985 .

Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model

S. Wyrick, S. Chaney, F. Luo, 1999, Cancer Chemotherapy and Pharmacology.

High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand.

S. Wyrick, S. Chaney, A. Sancar, 1986, Analytical biochemistry.

Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats

S. Wyrick, S. Chaney, F. Luo, 1999, Cancer Chemotherapy and Pharmacology.

Biotransformations of oxaliplatin in rat blood in vitro

S. Wyrick, S. Chaney, F. Luo, 1999, Journal of biochemical and molecular toxicology.

Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in Fischer 344 rats.

S. Wyrick, S. Chaney, P. F. Carfagna, 1991, Journal of biochemical toxicology.

A novel phenylaminotetralin (PAT) recognizes histamine H1 receptors and stimulates dopamine synthesis in vivo in rat brain

S. Wyrick, N. Choksi, R. Booth, 2000, Brain Research.

Hypolipidemic activity of 6-substituted 6,7-dihydro-5H-dibenz[c,e]azepine and the effects of 6,7-dihydro-5H-dibenz[c,e]azepine on lipid metabolism of rodents.

S. Wyrick, I. Hall, A. R. Murthy, 1986, Journal of pharmaceutical sciences.

Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma.

S. Wyrick, S. Chaney, D. Thompson, 1995, Cancer research.

Synthesis of tritiated cromolyn diethyl ester

S. Wyrick, V. Ranga, 1984 .

New sigma-like receptor recognized by novel phenylaminotetralins: ligand binding and functional studies.

A. M. Myers, R. Mailman, R. Baldessarini, 1993, Molecular pharmacology.

Hypolipidemic activity of in vitro inhibitors of hepatic and intestinal sn-glycerol-3-phosphate acyltransferase and phosphatidate phosphohydrolase.

C. Piantadosi, S. Wyrick, R. G. Lamb, 1977, Atherosclerosis.

Hypolipidemic activity of phthalimide derivatives V: Reduced and hydrolytic products of simple cyclic imides.

S. Wyrick, J. Maguire, I. Hall, 1984, Journal of pharmaceutical sciences.

Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.

J P Bowen, R. Mailman, P. Charifson, 1988, Journal of medicinal chemistry.

Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues.

S. Wyrick, I. Hall, G. Cocolas, 1984, Journal of medicinal chemistry.

Synthesis of [195mPt]-tetraplatin

S. Wyrick, S. Chaney, 1990 .

Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.

J P Bowen, R. Mailman, P. Charifson, 1989, Journal of medicinal chemistry.

Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.

R. Dingledine, C. McBain, S. Wyrick, 1989, Molecular pharmacology.

Tritiated platinum antitumor agents containing the trans‐(d,1)‐1,2‐diaminocyclohexane carrier ligand

S. Wyrick, S. Chaney, 1988 .

Cytoxicity of [(5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H fluoren-7-yl)oxy]acetic acid, an agent known to reduce brain edema.

S. Wyrick, I. Hall, 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Synthesis of Trimethylamine-[14C]carboxyborane and Trimethylamine-[14C]carboxymethoxyborane and L1210 Leukemia Cell Uptake

S. Wyrick, I. Hall, A. Sood, 1996 .

An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.

S. Wyrick, S. Chaney, P. Podhasky, 1991, Cancer research.

The Hypolipidemic Activity of a Series of 2,3-Dihydrophthalazine-l,4-dione Derivatives in Rodents

S. Wyrick, I. Hall, J. Chapman, 1986, Pharmaceutical Research.

The Hypolipidemic Activity of N-(p-Chlorobenzoyl)-sulfamate in Rodents and its Effect on Lipid Metabolism

S. Wyrick, I. Hall, A. Dubey, 2004, Pharmaceutical Research.

Biological activity of the hypolipidemic agent, N2-n-butylindazolone.

S. Wyrick, I. Hall, W. Williams, 1984, Journal of pharmaceutical sciences.

Antihyperlipidemic activity of o-chlorobenzylsulfonamide in rodents.

S. Wyrick, I. Hall, A. Dubey, 1984, Journal of pharmaceutical sciences.

Synthesis of [2-14C]-2′-deoxycytidine-3N-cyanoborane

S. Wyrick, I. Hall, A. Sood, 1991 .

Synthesis of [14C]‐N‐[(trimethylamineboryl) carbonyl]‐phenylalanine‐methyl ester

S. Wyrick, I. Hall, M. C. Miller, 1992 .

The cytotoxicity of [(N-alkyl-1,3-dioxo-1H,3H-isoindolin-5-yl)oxy]-alkanoic acids in murine and human tissue cultured cell lines.

S. Wyrick, I. Hall, 1995, Anticancer research.

Effects of [(N-alkyl-1,3-dioxo-1H,3H-isoindolin-5-yl)oxy]alkanoic acids, [(N-alkyl-1-oxo-1H,3H-isoindolin-5-yl)oxy]butanoic acids, and related derivatives on chloride influx in primary astroglial cultures.

S. Wyrick, A. Grippo, W. E. Kemp, 1987, Journal of medicinal chemistry.

Structure-activity relationships for binding and inactivation of rabbit reticulocyte ribosomes by quassinoid antineoplastic agents.

S. Wyrick, S. Chaney, K. Lee, 1983, European journal of biochemistry.

Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.

C. R. Bagnell, S. Wyrick, S. Chaney, 1998, Toxicological sciences : an official journal of the Society of Toxicology.

Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.

D E Nichols, R. Mailman, A. Tropsha, 1996, Journal of medicinal chemistry.

Hypolipidemic activity of N-substituted diphenimides in rodents

S. Wyrick, I. Hall, A. R. Murthy, 1985 .

Displacement of the bidentate malonate ligand from (d,l-trans-1,2-diaminocyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro.

S. Wyrick, S. Chaney, R. Voyksner, 1988, Biochemical pharmacology.

In Vitro Biotransformations Tetrachloro(d,l-fra/Â«)-l,2-diaminocyclohexaneplatinum(IV) (Tetraplatin) in Rat Plasma1

S. Wyrick, S. Chancy, G. K. Till, 2006 .

HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721).

S. Wyrick, S. Chaney, D. Thompson, 1995, Biochemical pharmacology.

diaminocyclohexaneplatinum(IV) (Tetraplatin) in Rat Plasma1

S. Wyrick, S. Chancy, G. K. Till, 1990 .

Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity.

A. M. Myers, R. Mailman, R. Baldessarini, 1993, Journal of medicinal chemistry.

Structure-activity studies on antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates, and benzylsulfonamides.

S. Wyrick, I. Hall, A. Dubey, 1984, Journal of Pharmacy and Science.

Hypolipidemic Agents of Phthalimide Derivatives 6. Effects of Aromatic vs. Non-Aromatic Imides

S. Wyrick, J. Maguire, I. Hall, 1984, Pharmaceutical Research.

Comparison of the hypolipidemic activity of cyclic vs. acyclic imides.

S. Wyrick, I. Hall, J. Chapman, 1985, Journal of medicinal chemistry.

Oral epithelial cell lipid synthesis in the presence of retinoic acid or nitrosonornicotine.

S. Wyrick, G. Schuster, J. Erbland, 1986, Journal of oral pathology.

Multiple tritium labelling of (+)‐7‐chloro‐8‐hydroxy‐1‐phenyl‐3‐methyl‐2,3,4,5‐tetrahydro‐1hZ‐3‐benzazepine (sch23390)

S. Wyrick, D. Mcdougald, R. Mallman, 1986 .

Tritium labelled (±)‐7‐chloro‐8‐hydroxy‐3‐methyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (SCH23390)

R. Mailman, S. Wyrick, 1985 .

Compounds that inhibit chymotrypsin and cell replication.

J. Katzenellenbogen, S. Wyrick, J A Katzenellenbogen, 1986, Biochemical pharmacology.

Synthesis of active site-directed organometallic irreversible protease inhibitors.

Y. J. Kim, S. Wyrick, C. Chae, 1979, Biochimica et biophysica acta.

Synthesis of tritiated bumetanide

S. Wyrick, P. Lauf, S. Morris-Natschke, 1984 .

Hypolipidemic activity of indan-1,3-dione derivatives in rodents.

S. Wyrick, I. Hall, A. R. Murthy, 1985, Journal of medicinal chemistry.

Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.

S. Wyrick, A. Tropsha, A Tropsha, 1999, Journal of medicinal chemistry.

Membrane actions of male contraceptive gossypol tautomers.

D. Benos, S. Wyrick, J. Reyes, 1986, Biochimica et biophysica acta.

Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.

D E Nichols, R. Mailman, P. Charifson, 1994, Journal of medicinal chemistry.

Conformational Analysis, Molecular Modeling, and Quantitative Structure–Activity Relationship Studies of Agents for the Inhibition of Astrocytic Chloride Transport

S. Wyrick, Hee-Moon Park, C. Waller, 2004, Pharmaceutical Research.

Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.

A. M. Myers, R. Baldessarini, P. Charifson, 1994, Journal of medicinal chemistry.

The preparation of tritium labeled methadone and its metabolites

S. Wyrick, C. G. Pitt, H. Seltzman, 1981 .

Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses

S. Wyrick, S. Chaney, A. Poma, 2004, Cancer Chemotherapy and Pharmacology.

Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor.

W. Blattner, J. Nadeau, C. Pui, 1988, Cancer research.

Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects.

R. Mailman, C. Kilts, S. Wyrick, 1986, Psychopharmacology bulletin.

The multiplicity of the D1 dopamine receptor.

R. Mailman, C. Kilts, S. Wyrick, 1986, Advances in experimental medicine and biology.

[3H]SCH23390 has the characteristics of a dopamine receptor ligand in the rat central nervous system.

S. Wyrick, R. Mailman, S D Wyrick, 1984, European journal of pharmacology.

A rapid and efficient method for the radiosynthesis and purification of [125I]SCH23982

R. Mailman, J. Gilmore, S. Wyrick, 1993, Journal of Neuroscience Methods.

Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity.

S. Wyrick, S. Morris-Natschke, K. Ishaq, 2001, Antiviral research.

Disposition of the Pharmacologically Active Compound [1-14C-Acetyl]-1-Acetyl-4-Phenyl-1,2,4-Triazolidine-3,5-Dione in CF1 Mice

S. Wyrick, I. Hall, Merrill C. Miller, 1994 .